Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant expression of human mannan-binding lectin.

T Vorup-Jensen1, E S Sørensen, U B Jensen

  • 1Department of Medical Microbiology and Immunology, University of Aarhus, Denmark. vorup@microbiology.au.dk

International Immunopharmacology
|May 19, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Milk osteopontin retains integrin-binding activity after in vitro gastrointestinal transit.

Journal of dairy science·2019
Same author

Lectin complement pathway proteins in healthy individuals.

Clinical and experimental immunology·2016
Same author

Oligomerization of Mannan-binding Lectin Dictates Binding Properties and Complement Activation.

Scandinavian journal of immunology·2016
Same author

Collectin liver 1 and collectin kidney 1 and other complement-associated pattern recognition molecules in systemic lupus erythematosus.

Clinical and experimental immunology·2015
Same author

Osteopontin is highly susceptible to cleavage in bovine milk and the proteolytic fragments bind the αVβ₃-integrin receptor.

Journal of dairy science·2013
Same author

Mannan-binding lectin (MBL)-associated serine protease-1 (MASP-1), a serine protease associated with humoral pattern-recognition molecules: normal and acute-phase levels in serum and stoichiometry of lectin pathway components.

Clinical and experimental immunology·2012
Same journal

Corrigendum to "Eicosapentaenoic acid attenuates hyperoxia-induced lung injury via p38 MAPK/NF-κB-mediated regulation of glycolytic reprogramming" [Int. Immunopharmacol. 168(Part 2) (2026) 115903].

International immunopharmacology·2026
Same journal

ENOX1 promotes gastric cancer progression via Snail2-mediated epithelial-mesenchymal transition and M2-type tumour-associated macrophages polarisation.

International immunopharmacology·2026
Same journal

Esketamine protects against LPS-induced septic lung injury via NMDA receptor and NF-κB/NLRP3/Caspase-1/GSDMD pathway.

International immunopharmacology·2026
Same journal

Ganoderic acid A alleviates metabolic dysfunction-associated fatty liver disease through attenuating steatosis and cellular apoptosis by targeting acetyl-CoA carboxylase.

International immunopharmacology·2026
Same journal

Podophyllotoxin-induced nephrotoxicity via the microbiota-gut-kidney axis in SD rats based on the toxicological evidence chain (TEC) concept.

International immunopharmacology·2026
Same journal

The immunopharmacological role of B-cell and neutrophil-derived extracellular vesicles in pancreatic cancer: Mechanisms of inflammation, tumor progression, and potential therapeutic targets.

International immunopharmacology·2026
See all related articles

Recombinant mannan-binding lectin (MBL) produced in human embryonic kidney cells closely mimics natural MBL. This advancement offers a promising alternative for MBL reconstitution therapy, overcoming limitations of plasma-derived MBL.

Area of Science:

  • Immunology
  • Biochemistry
  • Biotechnology

Background:

  • Mannan-binding lectin (MBL) is crucial for innate immunity, mediating complement deposition on microbes.
  • MBL deficiency is common, linked to recurrent infections and impaired immune complex clearance.
  • Plasma-derived MBL faces challenges like viral contamination and limited production capacity.

Purpose of the Study:

  • To compare recombinant MBL (rMBL) structures produced in different cell lines.
  • To identify a production method yielding rMBL functionally and structurally similar to natural MBL.
  • To establish a viable recombinant source for MBL reconstitution therapy.

Main Methods:

  • Synthesis of rMBL in myeloma, Chinese hamster ovary (CHO), human hepatocyte, and human embryonic kidney (HEK) cells.

Related Experiment Videos

  • Structural and functional characterization of synthesized rMBL variants.
  • Purification using selective carbohydrate affinity chromatography.

    • Main Results:

    • Recombinant MBL produced in HEK cells demonstrated structural and functional similarity to natural MBL.
    • Previous rMBL production methods resulted in proteins differing from the natural form.
    • Selective carbohydrate affinity chromatography enhanced the quality of HEK-derived rMBL.

    Conclusions:

    • Human embryonic kidney cells are a suitable host for producing clinically relevant rMBL.
    • rMBL produced in HEK cells, purified by affinity chromatography, represents a viable alternative to plasma-derived MBL.
    • This study paves the way for improved MBL-based immunotherapies.